167 related articles for article (PubMed ID: 32541169)
21. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer.
Hirahara T; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kita Y; Mori S; Sasaki K; Omoto I; Kurahara H; Maemura K; Okubo K; Uenosono Y; Ishigami S; Natsugoe S
BMC Cancer; 2019 Jul; 19(1):672. PubMed ID: 31286873
[TBL] [Abstract][Full Text] [Related]
22. Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer.
Inoue D; Sekiguchi S; Yamagata W; Maeda G; Yamada D; Fujiwara S; Itou S; Kurihara M; Hijioka Y; Shimoji K; Fujiki J; Nakazono A; Horike H; Yoshioka A; Ogura Y; Hatao F; Imamura K; Namiki S
Oncology; 2019; 96(3):140-146. PubMed ID: 30368510
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study.
Ogata T; Satake H; Ogata M; Hatachi Y; Inoue K; Hamada M; Yasui H
Oncotarget; 2018 Oct; 9(77):34520-34527. PubMed ID: 30349646
[TBL] [Abstract][Full Text] [Related]
24. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
25. Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer.
Cho IR; Park JC; Park CH; Jo JH; Lee HJ; Kim S; Shim CN; Lee H; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2014 Oct; 17(4):703-10. PubMed ID: 24442663
[TBL] [Abstract][Full Text] [Related]
26. Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study.
Nakazawa N; Sohda M; Tateno K; Watanabe T; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sano A; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Feb; 43(2):927-934. PubMed ID: 36697068
[TBL] [Abstract][Full Text] [Related]
27. Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
Hwang GY; Baek DW; Cho HJ; Lee SJ; Chae YS; Kang BW; Lee IH; Kim JG; Seo AN; Bae HI; Park KB; Park JY; Kwon OK; Lee SS; Chung HY
Anticancer Res; 2018 May; 38(5):3151-3156. PubMed ID: 29715156
[TBL] [Abstract][Full Text] [Related]
28. Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer.
Magdy M; Hussein T; Ezzat A; Gaballah A
J Gastrointest Cancer; 2019 Dec; 50(4):763-768. PubMed ID: 30058031
[TBL] [Abstract][Full Text] [Related]
29. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
30. [Neutrophil-to-Lymphocyte Ratio(NLR)as a Predictive Indicator of the Response to Nivolumab in Patients with Oral Squamous Cell Carcinoma].
Tachinami H; Tomihara K; Ikeda A; Sekido K; Sakurai K; Imaue S; Fujiwara K; Hayashi R; Noguchi M
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1485-1490. PubMed ID: 34911916
[TBL] [Abstract][Full Text] [Related]
31. Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
Arigami T; Matsushita D; Okubo K; Yanagita S; Ehi K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Uenosono Y; Ishigami S; Natsugoe S
Oncology; 2020; 98(9):630-636. PubMed ID: 32428899
[TBL] [Abstract][Full Text] [Related]
32. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.
Tokumaru S; Koizumi T; Sekino Y; Takeuchi N; Nakata S; Miyagawa Y; Kitazawa M; Muranaka F; Nakamura S; Koyama M; Yamamoto Y; Ehara T; Hondo N; Soejima Y
Oncology; 2021; 99(10):632-640. PubMed ID: 34280933
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer.
Zhang Y; Lu JJ; Du YP; Feng CX; Wang LQ; Chen MB
Medicine (Baltimore); 2018 Mar; 97(12):e0144. PubMed ID: 29561419
[TBL] [Abstract][Full Text] [Related]
35. Predictive biomarkers for the efficacy of nivolumab as ≥ 3
Kim JH; Ryu MH; Park YS; Ma J; Lee SY; Kim D; Kang YK
BMC Cancer; 2022 Apr; 22(1):378. PubMed ID: 35397540
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
Grenader T; Waddell T; Peckitt C; Oates J; Starling N; Cunningham D; Bridgewater J
Ann Oncol; 2016 Apr; 27(4):687-92. PubMed ID: 26787231
[TBL] [Abstract][Full Text] [Related]
37. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
Fujii H; Makiyama A; Iihara H; Okumura N; Yamamoto S; Imai T; Arakawa S; Kobayashi R; Tanaka Y; Yoshida K; Suzuki A
Anticancer Res; 2020 Dec; 40(12):7067-7075. PubMed ID: 33288604
[TBL] [Abstract][Full Text] [Related]
38. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
[TBL] [Abstract][Full Text] [Related]
39. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
40. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer.
Huang Z; Liu Y; Yang C; Li X; Pan C; Rao J; Li N; Liao W; Lin L
BMC Cancer; 2018 May; 18(1):515. PubMed ID: 29720123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
